Meeting
2021 Gastrointestinal Cancers Symposium
A phase I study of safety and immunogenicity of survivin long peptide vaccine (SurVaxM) in patients (pts) with metastatic neuroendocrine tumors (NETs).
Authors
Medhavi Gupta
Roswell Park Cancer Institute, Dept. of Medicine, Buffalo, NY
Medhavi Gupta , Robert Alan Fenstermaker , Jing-Xin Qiu , Renuka V. Iyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Neuroendocrine/Carcinoid
Track
Neuroendocrine/Carcinoid
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03879694
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr TPS375)
DOI
10.1200/JCO.2021.39.3_suppl.TPS375
Abstract #
TPS375
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.
First Author: Francesca Corti
Poster
2021 ASCO Annual Meeting
Phase I study of autolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium.
First Author: Timothy Jay Price
Poster
2019 ASCO Annual Meeting
A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 results.
First Author: Timothy Jay Price
Poster
2018 Gastrointestinal Cancers Symposium
Safety of trifluridine/tipiracil (TAS-102) in combination with temozolomide for metastatic neuroendocrine tumors.
First Author: Nataliya Volodymyrivna Uboha